Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2021-10-21 | Reverse | 1:2 |
| 2020-07-31 | Forward | 2499:1000 |
| 2019-10-29 | Forward | 2:1 |
Tiziana Life Sciences Ltd is a UK-based biotech company developing therapies for oncology and immunology, including Foralumab, Milciclib, and anti-IL6R antibodies for diseases like Crohn’s, MS, cancer, and COVID-19.

Intranasal Foralumab, Tiziana Life Sciences' lead Phase 2 drug, is a nasal spray anti-CD3 antibody targeting neuroinflammation in diseases like SPMS and Alzheimer's.
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
IMMX | $13.94 | COMPARE |
ZNTL | $3.80 | COMPARE |
WHWK | $4.62 | COMPARE |
MGNX | $4.13 | COMPARE |
COYA | $4.59 | COMPARE |
PLRX | $1.11 | COMPARE |
EXOZ | $7.17 | COMPARE |
OKYO | $1.67 | COMPARE |